Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:PD-166866
go back to main search page
Accession:CHEBI:156259 term browser browse the term
Definition:A member of the class of pyridopyrimidines that is pyrido[2,3-d]pyrimidine substituted by an amino group at position 2, 3,5-dimethoxyphenyl group at position 6, and by a (tert-butylcarbamoyl)nitrilo group at position 7. It is a selective ATP competitive inhibitor of the human fibroblast growth factor-1 receptor (FGFR1) tyrosine kinase with an IC50 of 52.4 nM.
Synonyms:exact_synonym: 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea
 related_synonym: 1-[2-amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea;   Formula=C20H24N6O3;   InChI=1S/C20H24N6O3/c1-20(2,3)26-19(27)25-17-15(8-12-10-22-18(21)24-16(12)23-17)11-6-13(28-4)9-14(7-11)29-5/h6-10H,1-5H3,(H4,21,22,23,24,25,26,27);   InChIKey=NHJSWORVNIOXIT-UHFFFAOYSA-N;   N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea;   PD166866;   SMILES=O=C(NC(C)(C)C)NC=1N=C2N=C(N=CC2=CC1C3=CC(OC)=CC(OC)=C3)N
 xref: CAS:192705-79-6
 xref_mesh: MESH:C113399
 xref: PMID:11063616;   PMID:11384237;   PMID:11404258;   PMID:12805413;   PMID:15773903;   PMID:15780636;   PMID:17964795;   PMID:17987803;   PMID:20003343;   PMID:21967732;   PMID:22876277;   PMID:23421678;   PMID:24719266;   PMID:26993162;   PMID:32572027;   PMID:9655904



show annotations for term's descendants           Sort by:
 
PD-166866 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Fgf1 fibroblast growth factor 1 multiple interactions EXP PD 166866 inhibits the reaction [FGF1 protein results in increased abundance of Nitric Oxide]; PD 166866 inhibits the reaction [FGF1 protein results in increased expression of and results in increased secretion of NGF protein]; PD 166866 inhibits the reaction [FGF1 protein results in increased expression of FGFR1 protein]; PD 166866 inhibits the reaction [FGF1 protein results in increased expression of NOS2 mRNA]; PD 166866 inhibits the reaction [FGF1 protein results in increased expression of POSTN mRNA] CTD PMID:15121739 PMID:15773903 PMID:16524372 NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
JBrowse link
G Fgfr1 Fibroblast growth factor receptor 1 decreases activity
multiple interactions
ISO
EXP
PD 166866 results in decreased activity of FGFR1 protein
PD 166866 inhibits the reaction [FGF1 protein results in increased expression of FGFR1 protein]; PD 166866 inhibits the reaction [FGFR1 protein results in increased phosphorylation of FGFR1 protein]
CTD PMID:12805413 PMID:15522930 PMID:15773903 NCBI chr16:66,492,445...66,546,731
Ensembl chr16:66,494,042...66,547,350
JBrowse link
G Ngf nerve growth factor multiple interactions EXP PD 166866 inhibits the reaction [FGF1 protein results in increased expression of and results in increased secretion of NGF protein] CTD PMID:15773903 NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions EXP PD 166866 inhibits the reaction [FGF1 protein results in increased expression of NOS2 mRNA] CTD PMID:16524372 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Postn periostin multiple interactions EXP PD 166866 inhibits the reaction [FGF1 protein results in increased expression of POSTN mRNA] CTD PMID:15121739 NCBI chr 2:138,527,714...138,559,098
Ensembl chr 2:138,527,696...138,559,099
JBrowse link
PD173074 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions ISO [arsenic trioxide results in increased susceptibility to PD 173074] which results in decreased expression of BIRC5 protein CTD PMID:27794399 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO [PKI 166 co-treated with PD 173074] results in decreased expression of CCND1 protein CTD PMID:15377668 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Fgf1 fibroblast growth factor 1 multiple interactions ISO PD 173074 inhibits the reaction [FGF1 protein results in increased phosphorylation of FGFR4 protein] CTD PMID:15709206 NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
JBrowse link
G Fgfr1 Fibroblast growth factor receptor 1 decreases activity
decreases expression
multiple interactions
ISO PD 173074 results in decreased activity of FGFR1 protein
PD 173074 results in decreased expression of FGFR1 protein
[PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]; Arsenic Trioxide promotes the reaction [PD 173074 results in decreased expression of FGFR1 protein]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of FGFR1 protein]
CTD PMID:22683780 PMID:27794399 NCBI chr16:66,492,445...66,546,731
Ensembl chr16:66,494,042...66,547,350
JBrowse link
G Fgfr3 fibroblast growth factor receptor 3 decreases activity ISO PD 173074 results in decreased activity of FGFR3 protein CTD PMID:15029211 NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341
JBrowse link
G Fgfr4 fibroblast growth factor receptor 4 multiple interactions
decreases activity
ISO PD 173074 inhibits the reaction [FGF1 protein results in increased phosphorylation of FGFR4 protein]
PD 173074 results in decreased activity of FGFR4 protein
CTD PMID:15377668 PMID:15709206 NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] CTD PMID:22683780 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
JBrowse link
G Mapk1 mitogen activated protein kinase 1 decreases phosphorylation
decreases expression
multiple interactions
ISO PD 173074 results in decreased phosphorylation of MAPK1 protein
PD 173074 results in decreased expression of MAPK1 protein
PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK1 protein]
CTD PMID:15029211 PMID:25953896 PMID:27794399 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases phosphorylation
decreases expression
multiple interactions
ISO PD 173074 results in decreased phosphorylation of MAPK3 protein
PD 173074 results in decreased expression of MAPK3 protein
PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK3 protein]
CTD PMID:15029211 PMID:25953896 PMID:27794399 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions ISO [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] CTD PMID:22683780 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [arsenic trioxide co-treated with PD 173074] results in increased expression of PARP1 protein modified form; [arsenic trioxide results in increased susceptibility to PD 173074] which results in increased expression of PARP1 protein modified form; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in increased expression of PARP1 protein modified form CTD PMID:27794399 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Phlpp1 PH domain and leucine rich repeat protein phosphatase 1 multiple interactions ISO PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK1 protein]; PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK3 protein] CTD PMID:25953896 NCBI chr13:22,308,532...22,530,978
Ensembl chr13:22,308,548...22,530,977
JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase decreases expression
multiple interactions
ISO PD 173074 results in decreased expression of RAF1 protein; PD 173074 results in decreased expression of RAF1 protein modified form
[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein; [arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form; [arsenic trioxide results in increased susceptibility to PD 173074] which results in decreased expression of RAF1 protein; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in decreased expression of RAF1 protein; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in decreased expression of RAF1 protein modified form; arsenic trioxide promotes the reaction [PD 173074 results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein]
CTD PMID:27794399 NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 multiple interactions ISO [PKI 166 co-treated with PD 173074] results in decreased activity of RPS6KB1 protein CTD PMID:15377668 NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions
decreases expression
ISO [Arsenic Trioxide co-treated with PD 173074] results in decreased expression of SRC protein; [Arsenic Trioxide results in increased susceptibility to PD 173074] which results in decreased expression of SRC protein; [PD 173074 results in increased susceptibility to Arsenic Trioxide] which results in decreased expression of SRC protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Arsenic Trioxide co-treated with PD 173074] results in decreased expression of SRC protein]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of SRC protein modified form]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of SRC protein]
PD 173074 results in decreased expression of SRC protein; PD 173074 results in decreased expression of SRC protein modified form
CTD PMID:27794399 NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
JBrowse link
G Tbx3 T-box transcription factor 3 multiple interactions ISO PD 173074 inhibits the reaction [afimoxifene results in increased expression of TBX3 protein]; PD 173074 inhibits the reaction [Estrogens results in increased expression of TBX3 protein] CTD PMID:21098263 NCBI chr12:36,879,924...36,894,849
Ensembl chr12:36,881,445...36,893,708
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide promotes the reaction [PD 173074 inhibits the reaction [Sodium Chloride results in increased expression of VEGFA mRNA]]; PD 173074 inhibits the reaction [Sodium Chloride results in increased expression of VEGFA mRNA] CTD PMID:26800359 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 20056
    role 20008
      biological role 20007
        biochemical role 19640
          apoptosis inducer 13408
            PD-166866 20
              PD173074 17
Path 2
Term Annotations click to browse term
  CHEBI ontology 20056
    subatomic particle 20054
      composite particle 20054
        hadron 20054
          baryon 20054
            nucleon 20054
              atomic nucleus 20054
                atom 20054
                  main group element atom 19956
                    p-block element atom 19956
                      carbon group element atom 19882
                        carbon atom 19875
                          organic molecular entity 19875
                            organic group 18961
                              organic divalent group 18947
                                organodiyl group 18947
                                  carbonyl group 18900
                                    carbonyl compound 18900
                                      carboxylic acid 18594
                                        carboacyl group 17706
                                          univalent carboacyl group 17706
                                            carbamoyl group 17546
                                              carboxamide 17546
                                                monocarboxylic acid amide 15515
                                                  urea 5134
                                                    ureas 5132
                                                      PD-166866 20
                                                        PD173074 17
paths to the root